MILAN — Antidepressants escitalopram and duloxetine have been shown to improve verbal memory in moderate to severe depression, a clinical effect linked to changes in serotonin 4 (5-HT4) receptor ...
Researchers have found that SSRI (Selective Serotonin Reuptake Inhibitors) antidepressants have the potential to improve certain cognitive functions, such as verbal memory. They measured brain ...
The company states: “Silo Pharma (SILO) announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor, 5-HT4R, and the NMDA ...
A study published in Biological Psychiatry investigated the role of the 5-HT4 receptor (5-HT4R) in patients with major depressive disorder (MDD) and how changes in this receptor may relate to the ...
(RTTNews) - First Wave BioPharma, Inc., (FWBI) announced an agreement with Sanofi (SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop ...
Several 5-HT4 receptor (5-HT4R) agonists are approved for treating chronic idiopathic constipation (CIC) by stimulating gastrointestinal (GI) motility. Traditional 5-HT4R agonists act systemically, ...
First Wave BioPharma Inc (NASDAQ:FWBI) announced an agreement with Sanofi SA (NASDAQ:SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop ...
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio ...
Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results